frontline treatment for cll: the changing paradigm
Published 2 months ago • 369 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
2:04
introducing a phase ib/ii trial to evaluate tasquinimod for the treatment of myelofibrosis
-
6:44
the current landscape for the treatment of r/r aml in the post-transplant setting
-
0:55
the role of clinical trials in improving treatment options for scd
-
1:04
clad-ldac-ven induction therapy in aml: insights from a phase ii trial
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
3:07
barriers to progressing cll treatment in taiwan: treatment access and biomarkers
-
1:48
do all patients require maintenance therapy following allosct?
-
3:16
the optimization of induction chemotherapy for patients with aml
-
2:29
application animation ct motion™ part 5: start of injection
-
9:55
minimum requirements, fees , scholarships? (part 1)
-
17:36
uoc: my journey as a medical student // dramas and struggles // how the systems works
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
1:44
the impact of liso-cel approval on the cll treatment landscape and barriers to its use
-
0:47
overview of the phase iii enhance trial schema
-
1:18
involving the patient in treatment decisions for cll
-
0:53
improving quality of life outcomes for patients with scd
-
1:43
oral therapies in the future of aml treatment
-
1:56
the future of fixed-duration therapy in cll
-
2:04
murano trial: revolutionizing the standard of care for relapsed cll patients
-
1:26
the impact of comorbidity burden on treatment decisions in cll
-
1:26
improving outcomes in sickle cell disease: expanding access and expediting treatment development
-
0:56
fixed-duration treatment strategies for frontline and relapsed cll